ClinicalTrials.gg
CompletedNCT07011992Updated Aug 14, 2025

A Study to Assess the Effects of BPN14770 on Rosuvastatin

A Phase 1 interventional study of Rosuvastatin and BPN14770 in Healthy Participants, sponsored by Shionogi. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Shionogi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of this study is to investigate the effects of BPN14770 on the pharmacokinetics of the breast cancer resistance protein and organic anion transporting polypeptide 1B1 substrate rosuvastatin in healthy adults.

02

Conditions studied

  • Healthy Participants

Keywords

  • BPN14770
  • Rosuvastatin
  • Pharmacokinetics
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Overtly healthy as determined by medical evaluation including medical history, medical examination, laboratory tests, vital sign measurements, and 12-lead at screening and on admission or participants whose laboratory values exceed the institutional reference range but deemed not by the investigator in consideration of safety
  • ≥18.5 and \<32.0 kilograms/meter squared
  • All female participants must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations)

Key Exclusion Criteria:

  • Presence or history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological, or ophthalmological (that is, increased intraocular pressure) disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data per the investigator's assessment
  • Known history of allergic reaction to multiple medications and/or severe allergic reaction to any food or environmental allergens
  • Prior use of rosuvastatin that was discontinued for tolerability or adverse events
  • Received ≥4 types of study interventions within 12 months prior to administration of study intervention
  • Positive drug or alcohol screen test result at screening or upon admission
  • Use of cannabis (medical or recreational), tobacco, or nicotine-containing products (including e-cigarettes, pipe tobacco, cigar, chewing tobacco, nicotine patch, and nicotine gum) within 6 months prior to admission

Note: Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    BPN14770

    Participants will receive rosuvastatin and BPN14770.

    Drug: Rosuvastatin · Drug: BPN14770

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of Rosuvastatin

    Time frame: Days 1 and 11 (pre-dose, up to 72 hours post-dose)

  2. Time to Maximum Plasma Concentration (Tmax) of Rosuvastatin

    Time frame: Days 1 and 11 (pre-dose, up to 72 hours post-dose)

Secondary outcomes

  1. Cmax of BPN14770

    Time frame: Day 11 (pre-dose, up to 72 hours post-dose)

  2. Tmax of BPN14770

    Time frame: Day 11 (pre-dose, up to 72 hours post-dose)

  3. Cmax of Coproporphyrin I

    Time frame: Days 1 and 11 (pre-dose, up to 72 hours post-dose)

  4. Tmax of Coproporphyrin I

    Time frame: Days 1 and 11 (pre-dose, up to 72 hours post-dose)

  5. Number of Participants Experiencing Treatment-emergent Adverse Events

    Time frame: Day 1 through Day 21

07

Study locations

1 site
  • ICON Clinical Research
    Lenexa, Kansas 66219, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Jul 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jun 10, 2025
StartActual
Jul 18, 2025
Primary completionActual
Jul 31, 2025
CompletionActual
Aug 7, 2025
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07011992
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Jun 10, 2025
Start date
Jul 18, 2025
Primary completion
Jul 31, 2025
Completion
Aug 7, 2025
Last update
Aug 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BPN14770

Start the discussion